2021 年第 3 期 第 16 卷

利妥昔单抗治疗原发性肾病综合征的研究进展

Research progress of rituximab in the treatment of primary nephrotic syndrome

作者：王晓菲张婷刘寻逯小英邹洪斌

英文作者：Wang Xiaofei Zhang Ting Liu Xun Lu Xiaoying Zou Hongbin

单位：吉林大学第二医院肾病内科130041

英文单位：Department of Nephrology the Second Hospital of Jilin University Changchun 130041 China

关键词：原发性肾病综合征；利妥昔单抗；不良反应

英文关键词：Primarynephroticsyndrome;Rituximab;Adversereaction

• 摘要：

• 原发性肾病综合征（PNS）是肾小球疾病的常见表现，临床上常将糖皮质激素作为一线治疗药物，多数患者需联合常规免疫抑制治疗，如环磷酰胺、钙调神经磷酸酶抑制剂等，即便如此，仍存在部分患者病情不能得到有效缓解。近年来利妥昔单抗作为一种新型治疗药物，逐渐被应用于难治性PNS的治疗，并取得良好的成效。本文就利妥昔单抗治疗PNS的机制、给药方案、在不同病理类型PNS中的应用及不良反应进行综述，以期为临床提供参考。

• Primary nephrotic syndrome(PNS) is a common manifestation of glomerular disease. Glucocorticoid is often used as a first-line treatment drug in clinic, and most patients need to be combined with conventional immunosuppressive therapy, such as cyclophosphamide, calcineurin inhibitors(CNI) and so on, but there are still some patients who are not in remission. In recent years, as a new therapeutic drugs, rituximab has been gradually used in the treatment of refractory PNS and achieves good results. This article reviews the mechanism, administration regimen, application in different pathological types and adverse reactions of rituximab in the treatment of PNS, in order to provide clinical reference.